NCT02360579Phase 2Completed

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Study sponsor: Iovance Biotherapeutics, Inc. · IOVA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-10-24Actual
Enrollment · participants220Actual
Source updated2026-03-25Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Actual enrollment increased by 42 participants

Before: 178 participants (actual). After: 220 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview